Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.

ABSTRACT:

Importance

In the era of immuno-oncology, imaging alone seems to be insufficient to capture treatment responses, as patients with stable disease treated with immunotherapy have a wide range of clinical outcomes. There is an unmet need for complementary (ideally cost-efficient) markers that enable assessment of therapy response and outcomes in conjunction with imaging.

Objectives

To examine whether longitudinal changes in the modified Glasgow prognostic score (mGPS), which is based on C-reactive protein and albumin, can predict responses and outcomes in patients with metastatic renal cell carcinoma (mRCC).

Design, setting, and participants

This post hoc analysis, conducted from October 2022 to April 2023, evaluated the prognostic and predictive performance of on-treatm

SUBMITTER: Saal J 

PROVIDER: S-EPMC10288377 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature